Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31204345 | 0.95 | EGFR (0.55) | EGFR | |
| SCHEMBL25001544 | 0.92 | EGFR (0.65) | EGFRBTK | |
| SCHEMBL30741317 | 0.92 | EGFR (0.65) | EGFRBTK | |
| SCHEMBL29785253 | 0.92 | EGFR (0.54) | EGFR | |
| SCHEMBL27091502 | 0.92 | EGFR (0.54) | EGFR | |
| SCHEMBL31204541 | 0.91 | EGFR (0.56) | EGFR | |
| SCHEMBL29785342 | 0.91 | EGFR (0.54) | EGFR | |
| SCHEMBL27091490 | 0.91 | EGFR (0.54) | EGFR | |
| SCHEMBL31204418 | 0.91 | EGFR (0.53) | EGFR | |
| SCHEMBL30741330 | 0.91 | EGFR (0.58) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2024259216-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885BTK 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.